FDA Class III Recall: Rising Pharma's Pregabalin Capsules Contaminated with Foreign Tablets, Impacting US Supply Chain
Rising Pharma Holdings, Inc. has initiated a voluntary Class III recall (D-0541-2024) for specific lots of Pregabalin Capsules 50mg distributed nationwide in the USA. This action stems from the discovery of a 20mg pantoprazole tablet within a bottle of Pregabalin, highlighting critical quality control failures at the manufacturing level. This event necessitates immediate supply chain risk assessment for procurement and regulatory teams.
FDA Identifies Critical Quality Breach in Rising Pharma's Pregabalin Supply
On May 16, 2024, Rising Pharma Holdings, Inc., headquartered in East Brunswick, NJ, initiated a voluntary Class III recall, designated D-0541-2024, for specific lots of its Pregabalin Capsules 50mg. This action was prompted by a significant quality control failure: the discovery of a foreign tablet, identified as a 20mg pantoprazole tablet, within a 1000-count bottle of Pregabalin Capsules. The contamination was detected by a re-packager, American Health Packaging (AHP), during their packaging setup process. The affected product, bearing NDC 64980-411-10, is from Lot 23132611 with an expiration date of July 31, 2026. This incident underscores a critical lapse in Good Manufacturing Practices (GMP) at the point of manufacture, raising immediate concerns for pharmaceutical procurement and regulatory affairs teams. For your business, this means an urgent need to verify the integrity of your current Pregabalin inventory and assess the robustness of your supplier qualification processes, particularly for generic medications where cross-contamination risks can impact patient safety and product efficacy. While classified as Class III, indicating a low probability of serious adverse health consequences, the presence of a foreign drug substance represents a fundamental breakdown in quality assurance that cannot be overlooked.
Manufacturing & Distribution Profile: Rising Pharma's Global Generic Pregabalin Network
Rising Pharma Holdings, Inc. serves as the marketer and distributor for the recalled Pregabalin Capsules across the United States. The actual manufacturing of the affected product, Pregabalin Capsules 50mg, is attributed to Laurus Labs Limited, located in Anakapalli-531011, India. This global manufacturing arrangement is common within the generic pharmaceutical industry but introduces inherent complexities and risks. Pregabalin, a generic equivalent to Lyrica, is a critical medication used for treating neuropathic pain, fibromyalgia, and seizures, making its consistent and safe supply paramount. The recall impacts various strengths and package configurations, including product NDC codes 64980-410 through 64980-417, distributed nationwide. For procurement directors, this event highlights the imperative of stringent oversight over contract manufacturing organizations (CMOs) like Laurus Labs. Your business must ensure that your supplier agreements include robust quality clauses, audit rights, and clear accountability for manufacturing deviations. Relying solely on a distributor's assurances without understanding the underlying manufacturing controls can expose your supply chain to unforeseen regulatory and quality risks, potentially leading to costly disruptions and reputational damage.
Supply Chain Exposure: Assessing Impact on Downstream Partners and Patient Access
The nationwide distribution pattern of Rising Pharma's Pregabalin Capsules means that numerous downstream partners, including wholesalers, pharmacies, and healthcare providers, are directly exposed to this recall. The detection by American Health Packaging (AHP), a re-packager, demonstrates that quality failures can propagate through multiple tiers of the supply chain before being identified. Businesses that have purchased or distributed Lot 23132611 of Pregabalin Capsules 50mg (NDC 64980-411-10) must immediately initiate quarantine procedures and coordinate returns with Rising Pharma. Beyond the immediate logistical challenges, this incident raises concerns about potential medication errors if a patient were to unknowingly ingest a pantoprazole tablet instead of Pregabalin. For supply chain VPs, this situation demands a comprehensive review of your product traceability systems and recall management protocols. The financial implications extend beyond product returns, encompassing potential chargebacks, administrative costs, and the intangible cost of eroded trust among healthcare providers and patients. Proactive communication with your network and swift action are crucial to mitigate further business disruption and maintain market confidence.
Mitigating Risk: Strategic Sourcing for Generic Pregabalin and Quality Assurance
Given the recall of Rising Pharma's Pregabalin, procurement teams must immediately evaluate their sourcing strategies for this critical molecule. While the ChemLifeIntel Knowledge Graph does not specify alternative suppliers for Pregabalin in relation to this event, the general principle of supply diversification becomes paramount. Businesses should identify and qualify multiple manufacturers for essential generic drugs to prevent single points of failure. This involves not only assessing manufacturing capacity but also conducting thorough audits of quality management systems, particularly for overseas facilities like Laurus Labs Limited in India. Qualification timelines for new suppliers can be extensive, often spanning 6-12 months, making a pre-vetted list of alternatives a strategic imperative. For procurement directors, this incident serves as a stark reminder to move beyond price-driven sourcing to a risk-adjusted approach that prioritizes robust quality controls and supply chain resilience. Investing in comprehensive supplier audits and maintaining a diversified supplier base for key active pharmaceutical ingredients (APIs) and finished drug products is essential to safeguard against similar disruptions and ensure uninterrupted patient access to vital medications.
Regulatory Compliance and Remediation: Actions for Rising Pharma and Laurus Labs
As the recalling firm, Rising Pharma Holdings, Inc. is responsible for the effective execution of the recall and communication with the FDA. However, the root cause of the contamination lies with the manufacturer, Laurus Labs Limited. Both entities will face intense scrutiny from the FDA regarding their Good Manufacturing Practices (GMP) and quality systems. The FDA will expect a thorough investigation into how a 20mg pantoprazole tablet could contaminate a bottle of Pregabalin Capsules, requiring a detailed root cause analysis, identification of contributing factors, and comprehensive Corrective and Preventive Actions (CAPAs). This investigation will likely focus on material handling, line clearance procedures, cleaning validation, and batch segregation protocols at the Laurus Labs facility in Anakapalli, India. For regulatory affairs heads, this means preparing a robust and transparent response to the FDA, detailing the corrective measures implemented. Failure to adequately address these issues could lead to further enforcement actions, including potential FDA Warning Letters, import alerts for Laurus Labs' products entering the U.S., or even additional recalls, significantly impacting their ability to supply the US market. Proactive engagement and demonstrable commitment to quality remediation are critical.
Market Impact and Future Outlook for Generic Pregabalin Supply
While a Class III recall typically carries a lower immediate risk to patient health, the nature of the defect—a foreign tablet—signals a serious quality system breakdown that could have broader market implications. The generic Pregabalin market is competitive, with multiple manufacturers supplying the active pharmaceutical ingredient (API) and finished dosage forms. An incident of this magnitude, even if isolated to a specific lot, can erode confidence in the affected brands and potentially shift market share. Business development executives should closely monitor the regulatory responses and remediation efforts of both Rising Pharma and Laurus Labs. Prolonged regulatory issues or a perception of systemic quality problems could lead to customers seeking more reliable suppliers. This event reinforces the importance of due diligence in partner selection, especially when evaluating generic drug portfolios. The broader trend of increased FDA scrutiny on global pharmaceutical supply chains, particularly those involving contract manufacturers in regions like India, suggests that similar quality-related incidents could trigger more severe consequences, influencing future sourcing strategies and market dynamics for essential generic medications.